Corkery et al. (2015a) identified PRP4K as a novel HER2-regulated protein in breast and ovarian cancer that when depleted could reduce the sensitivity of breast and ovarian cancer cells to the taxane paclitaxel. This evidence concerns the gene ERBB2 and ovarian carcinoma.